Vanda Pharmaceuticals (VNDA) Stock Price, Quote & News

Company Profile

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for prev...

Industry: Biotechnology

Sector: Healthcare

Phone: 202 734 3400

Website: www.vandapharma.com

Address:

2200 Pennsylvania Avenue NW, Suite 300E, Washington, United States

TomMac64 Jul. 4 at 10:29 AM

$JNJ $LLY $MRNA $VNDA Doesn’t have to be at $30 + what’s wrong with $15 + the OS float is 60M that’s after 20 years public …. AMAZING !

0 · Reply

Investor203 Jul. 4 at 5:39 AM

$MRNA who is buying $VNDA at $30+? $JNJ $LLY or someone else

0 · Reply

TomMac64 Jul. 3 at 10:04 AM

$VNDA Impressive !

0 · Reply

Tetoooo Jul. 3 at 3:04 AM

$VNDA low risk for dilution based on http://FinPile.ai app with some good sentiment and news so it might fly Monday

0 · Reply

aet Jul. 3 at 2:46 AM

$VNDA https://en.wikipedia.org/wiki/Mihael_Polymeropoulos

0 · Reply

mikesterz7 Jul. 3 at 2:24 AM

$VNDA yes 👍

0 · Reply

Investor203 Jul. 3 at 2:10 AM

$VNDA $LLY BO coming soon at $30

2 · Reply

StockHunter75 Jul. 3 at 2:00 AM

$VNDA I am very bullish here I think this is going to pop off soon.

0 · Reply

topstockalerts Jul. 3 at 1:38 AM

$VNDA this just keeps pushing without much effort

0 · Reply

TomMac64 Jul. 3 at 12:10 AM

$VNDA Yup !

0 · Reply

Vanda Pharmaceuticals Transcript: AGM 2026

2026-05-27T11:24:38.000Z - 5 weeks ago

Vanda Pharmaceuticals’ imsidolimab granted orphan drug designation in Japan

May 27, 2026, 7:00 AM EDT - 5 weeks ago

Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis

May 19, 2026, 2:00 PM EDT - 6 weeks ago

Vanda Pharmaceuticals Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

May 18, 2026, 7:00 AM EDT - 6 weeks ago

Vanda Pharmaceuticals Slides: Corporate presentation

2026-05-11T10:50:03.000Z - 7 weeks ago

Vanda Pharmaceuticals price target lowered to $21 from $24 at H.C. Wainwright

May 7, 2026, 6:44 PM EDT - 2 months ago

Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences

2026-05-07T01:52:21.000Z - 2 months ago

Vanda Pharmaceuticals reports Q1 EPS (82c) vs. (50c) last year

2026-05-07T01:50:55.000Z - 2 months ago

Vanda Pharmaceuticals raises FY26 revenue view to $240M-$290M from $230-$260M

May 6, 2026, 4:30 PM EDT - 2 months ago

Vanda Pharmaceuticals Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 2 months ago

Vanda Pharmaceuticals Earnings release: Q1 2026

May 6, 2026, 4:30 PM EDT - 2 months ago

Vanda Pharmaceuticals Quarterly report: Q1 2026

May 6, 2026, 4:01 PM EDT - 2 months ago

Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results

2026-05-04T12:46:08.000Z - 2 months ago

Vanda Pharmaceuticals announces U.S. commercial availability of Nereus

May 4, 2026, 8:00 AM EDT - 2 months ago

Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years

2026-05-01T20:40:19.000Z - 2 months ago

Vanda Pharmaceuticals announces commercial availability for Nereus

Apr 29, 2026, 4:30 PM EDT - 2 months ago

Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026

Apr 28, 2026, 7:12 PM EDT - 2 months ago

Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence

ANAB

Apr 23, 2026, 8:00 AM EDT - 2 months ago

Vanda Pharmaceuticals Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 2 months ago

Vanda Pharmaceuticals Proxy statement: Proxy filing

Apr 22, 2026, 5:13 PM EDT - 2 months ago

Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors

2026-04-09T15:10:15.000Z - 3 months ago

Vanda calls on FDA to remove proposal extending drug review timelines

Apr 9, 2026, 11:02 AM EDT - 3 months ago

Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines

2026-04-08T20:50:15.000Z - 3 months ago

Vanda Pharmaceuticals initiates trial of tradipitant in GLP-1-caused vomiting

Apr 8, 2026, 4:44 PM EDT - 3 months ago

Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists

Mar 19, 2026, 4:34 PM EDT - 3 months ago

Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods

Mar 11, 2026, 2:15 PM EDT - 4 months ago

Vanda Pharmaceuticals Transcript: The Citizens Life Sciences Conference 2026

Mar 6, 2026, 6:00 AM EST - 4 months ago

Vanda Pharmaceuticals Slides: Corporate presentation

2026-03-05T11:11:50.000Z - 4 months ago

Vanda Pharmaceuticals initiated with a Buy at Truist

2026-03-03T13:05:54.000Z - 4 months ago

Vanda Pharmaceuticals: FDA grants hearing to review sNDA for Hetlioz

Mar 3, 2026, 8:01 AM EST - 4 months ago

Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years

Feb 26, 2026, 4:35 PM EST - 4 months ago

Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference

2026-02-25T13:35:25.000Z - 4 months ago

Vanda Pharmaceuticals price target raised to $17 from $14 at B. Riley

2026-02-25T12:23:26.000Z - 4 months ago

Vanda announces FDA accepted BLA for imsidolimab

Feb 25, 2026, 7:18 AM EST - 4 months ago

Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

ANAB

Feb 23, 2026, 10:28 AM EST - 4 months ago

Vanda Pharmaceuticals stock's explosive rally may be more hype than substance

2026-02-23T11:10:11.000Z - 4 months ago

Vanda Pharmaceuticals price target raised to $24 from $22 at H.C. Wainwright

Feb 20, 2026, 6:03 PM EST - 4 months ago

US FDA approves Vanda's psychiatric drug

Feb 20, 2026, 5:59 PM EST - 4 months ago

Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation

Feb 12, 2026, 7:00 AM EST - 5 months ago

Vanda Pharmaceuticals Registration statement: Registration Filing

Feb 11, 2026, 4:30 PM EST - 5 months ago

Vanda Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 11, 2026, 4:30 PM EST - 5 months ago

Vanda Pharmaceuticals Annual report: Q4 2025

Feb 11, 2026, 4:30 PM EST - 5 months ago

Vanda Pharmaceuticals Earnings release: Q4 2025

Feb 11, 2026, 4:01 PM EST - 5 months ago

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 4, 2026, 6:01 PM EST - 5 months ago

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026

Jan 15, 2026, 12:00 PM EST - 6 months ago

Vanda Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 15, 2026, 7:00 AM EST - 6 months ago

Vanda Pharmaceuticals Slides: Corporate presentation

Jan 8, 2026, 9:31 AM EST - 6 months ago

Vanda and Exante Data Combine in Strategic Merger

Jan 8, 2026, 7:00 AM EST - 6 months ago

Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder

Dec 31, 2025, 10:57 AM EST - 6 months ago

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval

Dec 30, 2025, 6:30 PM EST - 6 months ago

US FDA approves Vanda Pharmaceuticals' motion sickness drug

Dec 30, 2025, 6:13 PM EST - 6 months ago

Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness

Dec 15, 2025, 7:00 AM EST - 7 months ago

Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

ANAB

Dec 11, 2025, 5:02 PM EST - 7 months ago

Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference

Dec 4, 2025, 4:21 PM EST - 7 months ago

FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness

Nov 28, 2025, 7:00 AM EST - 7 months ago

Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness

Nov 17, 2025, 6:37 PM EST - 8 months ago

Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting

Nov 12, 2025, 4:40 PM EST - 8 months ago

Vanda Pharmaceuticals Transcript: Stifel 2025 Healthcare Conference

Nov 9, 2025, 6:00 PM EST - 8 months ago

Vanda Pharmaceuticals Slides: Corporate Presentation

Nov 5, 2025, 5:00 PM EST - 8 months ago

Vanda Pharmaceuticals Announces Participation in the Stifel 2025 Healthcare Conference

Oct 29, 2025, 4:30 PM EDT - 8 months ago

Vanda Pharmaceuticals Earnings Call Transcript: Q3 2025

Oct 29, 2025, 4:30 PM EDT - 8 months ago

Vanda Pharmaceuticals Quarterly report: Q3 2025

Oct 29, 2025, 4:30 PM EDT - 8 months ago

Vanda Pharmaceuticals Earnings release: Q3 2025

Oct 29, 2025, 4:01 PM EDT - 8 months ago

Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results

Oct 22, 2025, 4:30 PM EDT - 9 months ago

Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025

Oct 8, 2025, 8:00 AM EDT - 9 months ago

Monumental Sports & Entertainment Taps D.C.'s Own Vanda Pharmaceuticals as Founding Partner to Help Drive the Creation of Brand-New Downtown Arena

Oct 1, 2025, 5:02 PM EDT - 9 months ago

Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration

Sep 25, 2025, 8:00 AM EDT - 10 months ago

Vanda Pharmaceuticals announces the publication in PLOS One of an article titled "Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial"

Sep 9, 2025, 8:30 AM EDT - 10 months ago

Vanda Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 4:30 PM EDT - 10 months ago

Vanda Pharmaceuticals Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 3, 2025, 3:55 PM EDT - 10 months ago

Vanda Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Aug 28, 2025, 5:23 PM EDT - 11 months ago

Vanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences

Aug 28, 2025, 7:00 AM EDT - 11 months ago

Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia Vera

Aug 21, 2025, 4:40 PM EDT - 11 months ago

Vanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision to Uphold Approval of Two Generic Versions of Hetlioz®

Aug 18, 2025, 7:00 AM EDT - 11 months ago

In a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder

Jul 31, 2025, 8:00 AM EDT - 1 year ago

Vanda Pharmaceuticals Earnings Call Transcript: Q2 2025

Jul 31, 2025, 8:00 AM EDT - 1 year ago

Vanda Pharmaceuticals Quarterly report: Q2 2025

Jul 31, 2025, 8:00 AM EDT - 1 year ago

Vanda Pharmaceuticals Earnings release: Q2 2025

Jul 31, 2025, 7:30 AM EDT - 1 year ago

Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results

Jul 23, 2025, 4:45 PM EDT - 1 year ago

Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025

Jun 10, 2025, 8:00 AM EDT - 1 year ago

Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S

May 27, 2025, 9:00 AM EDT - 1 year ago

Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting

May 27, 2025, 8:00 AM EDT - 1 year ago

Vanda Pharmaceuticals Proxy statement: Proxy Filing

May 16, 2025, 5:30 PM EDT - 1 year ago

Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Vanda Pharmaceuticals Earnings Call Transcript: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Vanda Pharmaceuticals Quarterly report: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Vanda Pharmaceuticals Earnings release: Q1 2025

May 7, 2025, 4:01 PM EDT - 1 year ago

Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results

May 5, 2025, 8:00 AM EDT - 1 year ago

Vanda Announces Bysanti™ NDA Filing; FDA Decision Expected in Early 2026

May 2, 2025, 8:46 AM EDT - 1 year ago

Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Vanda Pharmaceuticals Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Vanda Pharmaceuticals Proxy statement: Proxy Filing

Apr 23, 2025, 3:52 PM EDT - 1 year ago

FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA

TomMac64 Jul. 4 at 10:29 AM

$JNJ $LLY $MRNA $VNDA Doesn’t have to be at $30 + what’s wrong with $15 + the OS float is 60M that’s after 20 years public …. AMAZING !

0 · Reply

Investor203 Jul. 4 at 5:39 AM

$MRNA who is buying $VNDA at $30+? $JNJ $LLY or someone else

0 · Reply

TomMac64 Jul. 3 at 10:04 AM

$VNDA Impressive !

0 · Reply

Tetoooo Jul. 3 at 3:04 AM

$VNDA low risk for dilution based on http://FinPile.ai app with some good sentiment and news so it might fly Monday

0 · Reply

aet Jul. 3 at 2:46 AM

$VNDA https://en.wikipedia.org/wiki/Mihael_Polymeropoulos

0 · Reply

mikesterz7 Jul. 3 at 2:24 AM

$VNDA yes 👍

0 · Reply

Investor203 Jul. 3 at 2:10 AM

$VNDA $LLY BO coming soon at $30

2 · Reply

StockHunter75 Jul. 3 at 2:00 AM

$VNDA I am very bullish here I think this is going to pop off soon.

0 · Reply

topstockalerts Jul. 3 at 1:38 AM

$VNDA this just keeps pushing without much effort

0 · Reply

TomMac64 Jul. 3 at 12:10 AM

$VNDA Yup !

0 · Reply

TomMac64 Jul. 3 at 12:09 AM

$LUNR $RKLB $SLS $VNDA Purchased SLS in September 24’

0 · Reply

NasdaqNavigatorrr Jul. 2 at 9:03 PM

I’ve been aggressively pounding the table to buy $SLS under $1.80 and am now screaming even louder to load up on $VNDA at $6. Ignore this warning at your own peril—otherwise, you'll end up with the same regret as those who missed out on $SLS or $LUNR at $3, or $RKLB at $6.

2 · Reply

johnle66 Jul. 2 at 8:19 PM

$VNDA once again nearly 70K shares purchased last couple of minutes. Happens everyday.

0 · Reply

Unicorn2020 Jul. 2 at 7:48 PM

Estimated probability of a buyout occurring within the next 12 months $OCUL ⭐ Highest probability: 45-55%. $IOVA 35-45% - so close to OCUL. $NTLA 25-35% $VNDA 15-25%. This isn't because the assets lack value. The management has demonstrated a willingness to remain independent; previously resisted acquisition interest. Buyers know negotiations could be difficult.

0 · Reply

CapSampler Jul. 2 at 7:44 PM

$VNDA this is gonna run hard. I wouldn’t be surprised to see $70 a share. It’s been quietly aquaired from the market now, possibly until the purchase, merger.

0 · Reply

Unicorn2020 Jul. 2 at 6:43 PM

$VNDA filed for a mixed shelf offering of up to $200 million in securities on February 12, 2026, which allows the company to offer up to $200 million of securities from time to time for general corporate purposes. The company indicated that the net proceeds are intended for funding clinical programs, supporting commercial launches of their newer products like NEREUS and BYSANTI, and other R&D activities.

0 · Reply

cea Jul. 2 at 4:01 PM

$SLS $VNDA @VisionAlpha Don’t care what $VNDA is doing. 👎👎👎👎

1 · Reply

VisionAlpha Jul. 2 at 3:35 PM

$VNDA looks poised for a slow grind higher, similar to $SLS. Early positioning may matter before larger buyers step in and liquidity tightens. Bullish bias, but still needs confirmation.

0 · Reply

BullDonald Jul. 2 at 2:18 PM

$DPRO $ARVN $DPRO $BBAI $VNDA Go Greeeeen

0 · Reply

biid Jul. 2 at 10:40 AM

$VNDA Yes, this is how I would advertise if I were in charge of marketing for $VNDA . Maybe making the "motion sickness" wording a bit bigger, underlining it, and switching its place with the place of "50mg" would help as well.

1 · Reply

DataJim Jul. 2 at 9:25 AM

$GUTS Definitely thinking of getting in. It’s @BioRich top holding, and I share his interest in $TLSA and $VNDA https://chatgpt.com/share/6a462d86-4cf0-83e8-96e7-c053afb75ba8 I have made my decision after the linked conversation.

2 · Reply

TomMac64 Jul. 2 at 8:17 AM

$VNDA you mean like this ?

0 · Reply

Market Cap	373.44M
Revenue (ttm)	216.11M
Net Income (ttm)	-220.47M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-102.02%
Debt to Equity Ratio	0.00

Volume	859,100
Avg Vol	1,047,040
Day's Range	N/A - N/A
Shares Out	60.14M
Stochastic %K	95%
Beta	0.60
Analysts	Strong Sell
Price Target	$14.12